Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Other Non-Current Assets (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Other Non-Current Assets for 16 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 88.33% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, down 88.33%, and an annual FY2025 reading of $3.1 million, down 88.33% over the prior year.
  • Other Non-Current Assets was $3.1 million for Q4 2025 at Orthofix Medical, roughly flat from $3.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $45.4 million in Q1 2023 and bottomed at $2.5 million in Q1 2024.
  • Average Other Non-Current Assets over 5 years is $18.4 million, with a median of $20.6 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets skyrocketed 3826.09% in 2021, then crashed 94.5% in 2024.
  • Year by year, Other Non-Current Assets stood at $23.9 million in 2021, then rose by 7.71% to $25.7 million in 2022, then plummeted by 81.91% to $4.6 million in 2023, then skyrocketed by 469.2% to $26.5 million in 2024, then tumbled by 88.33% to $3.1 million in 2025.
  • Business Quant data shows Other Non-Current Assets for OFIX at $3.1 million in Q4 2025, $3.1 million in Q3 2025, and $3.1 million in Q2 2025.